CN105092848A - Method for detecting ERCC1/CEP19 gene status based on rare cell and correlated kit - Google Patents

Abstract

The invention relates to a method for detecting ERCC1/CEP19 (excision repair cross-complementing 1) gene status based on a rare cell and a correlated kit. The method comprises the following steps: step 1, acquiring a blood sample or a body fluid sample, wherein the sample contains a mixed cell population of circulating tumor cell (CTC) or other rare cells and leukocyte; step 2, using a buffer to dilute the sample, removing blood plasma, and recovering CTC or other rare cells; step 3, performing lysis by using a erythrocyte lysate, removing erythrocyte, and recovering CTC or other rare cells; step 4, uniformly mixing a magnetic particle coated with an anti-human-leucocyte correlated antigen-antibody with the recovered cell and performing incubation, so as to form a magnetic particle-leucocyte mixture through combination; step 5, centrifuging to separate the magnetic particle-leucocyte mixture from other cells, so as to obtain a mixed cell population containing CTC or other rare cells and a few of leucocytes; and step 6, using immunofluorescence cytochemistry and fluorescence in-situ hybridization combined method to determine the state of ERCC1/CEP19 and also identify CTC and other rare cells.

Description

A kind of method and related kit detecting ERCC1/CEP19 gene appearance based on rare cell

Technical field

The present invention relates to medical diagnostics, particularly the detection of tumour cell.More particularly, the present invention relates to the diagnostic method of the therapeutic scheme detecting cancer and assess patient.

Background technology

Circulating tumor cell (CirculatingTumorCell, CTC) refers to the tumour cell entering into blood circulation, and it can come off into blood by primary tumor or metastasis, also may advancing in blood in formation solid tumor focus.Tumour cell invades the circulation system, major part due to the Immune discrimination of body, machinery kill and wound and self apoptosis dead in a short time, only have only a few survive, and plant at far-end or former tissue and organ, being further development of metastasis, is the most direct factor causing metastases and recurrence.

CTC as a kind of " liquid biopsy " sample that can represent primary tumo(u)r, peripheral blood sample easily obtains, traumatic little, can repeatedly gather, be clinical detection more preferably Specimen origin, real-time comprehensive monitoring can be carried out to oncotherapy.Can effectively realize tumor recurrence early warning, curative effect is evaluated and tumor individual therapy medication guide in time, current CTC detect be widely used in clinical tumor patient curative effect Real-Time Evaluation, state of an illness Real-Time Monitoring, resistance factorial, in Index for diagnosis.

Fluorescence in situ hybridization (fluorescentinsituhybridization, FISH) is a kind of Cytogenetic techniques, can be used for carrying out detection and positioning to nucleic acid.FISH technology at present based on the rare cell that comes off is generally qualitative detection, is difficult to accomplish precisely quantitative and ensure its effect.Original position of searching to the bottom is to be applicable to the FISH detection method of tissue specimen and common exfoliative cytology FISH detection method at present, when after the cell smear of the order of magnitude between 0-100, and effectively cannot keep obtaining in cell balancing and keeping higher stability preferably at coloring effect, more be difficult to be formed the effectively stable shaped article quantitatively detected.Though have corresponding patent to set forth a kind of effective ways (US6 at present, 524,798), but need the special inspecting equipment of extremely sky high cost, cannot Routine Test Lab complete this based on and the FISH testing of a small amount of rare cell or even unicellular aspect.

Describe the authentication method of the tumour cell of biological sample, rare cells or other biological entity before this (as Chinese Patent Application No.: 200810097889.4,201310057307.0).This two-step approach requires that effective enrichment is to guarantee to obtain target cell before analysis, removes a large amount of fragment and other interfering materials simultaneously, makes to carry out cellular assay by imaging technique.With the negative enrichment strategy of uniqueness by immune magnetic particle and multi-density centrifugation, fluorescence in situ hybridization and Immunofluorescence analysis bank altogether, accurate quantification ground detects in nearly all variety of solid tumor types and drops to containing the rare cell (containing CTC) in the multiple biological fluid samples such as blood, chest/seroperitoneum, urine, cerebrospinal fluid the method.This combined method is used for the chromosome amplification type tumour cell in enrichment and counting blood sample, because herein is provided a kind of instrument measuring cancer.

ERCC1 (Excision repair cross-completion 1 gene) is first human DNA injury repair gene be found, and is positioned at No. 19 chromosome long arm, and its coded product is the single stranded DNA nucleic acid restriction endonuclease of high conservative.Research confirms, the rising of ERCC1 expression can cause the resistance to platinum-based chemotherapy, and namely the patient of low expression is more responsive to platinum medicine.So, detect ERCC1 gene expression dose and can be used for the curative effect that predicting tumors patient uses platinum medicine.

But during clinical detection, due to such as many situations that effectively cannot obtain tumor tissues such as excision, the not accomplice under duress of patient's subjective desire, and following limitation can be there is:

1, as having wound property and being limited to the histology of lesions position, there is specimen sampling and the limitation such as not easily maybe cannot to draw materials, and postoperatively can not repeatedly to draw materials, cause tissue sampling cannot provide the monitoring information of real-time.

2 and subject impact etc., the molecular information of tumour cell likely occurrence dynamics changes.As: studies have reported that, accept the patient with breast cancer of new adjuvant chemotherapy, before chemotherapy, accept biopsy, and result contrasted with postoperative pathological, before and after finding to there is treatment, ERCC1 expresses inconsistent situation.

3, the present situation of just local message reflection that causes of the existence of tumor tissues heterogeneity and single-point biopsy, makes traditional histological detect the evaluation lacking comprehensive globality, as the comprehensive evaluation etc. of primary tumor, multiple metastasis information.

The invention reside in while providing a kind of CTC of detection or other rare cells the method that quantity and the ratio of ERCC1/CEP19 detect.To obtain more comprehensively information.The present invention is being separated on the basis obtaining CTC (or other rare cells) in blood, carry out unicellular analysis of molecules, detect ERCC1 expression, come from individual cell level with this, immediately find the molecular information of ERCC1, to carry out Real Time Observation to the state of patient.

Summary of the invention

To the method that quantity and the ratio of ERCC1/CEP19 detect while the invention provides a kind of CTC of detection or other rare cells.Direct help clinician understands the real-time gene appearance of tumor patient, drafts next step therapeutic scheme with auxiliary prediction Survival.Method of the present invention comprises following whole and part steps:

Step 1, obtains blood sample from patient or other contain the body fluid sample of rare cell, comprises CTC or other rare cells and leukocytic mixed cellularity group in sample;

Step 2, uses damping fluid diluted sample, centrifugal segregation blood plasma, and reclaims CTC or other rare cells;

Step 3, uses erythrocyte cracked liquid cracking, and centrifugal segregation red blood cell also reclaims CTC or other rare cells;

Step 4, with the recovery cell blending incubation of magnetic particle with step 3 gained being coated with anti-human leucocyte associated antigen, fully to combine with target leucocyte to make magnetic particle and forms magnetic particle-leucocyte mixture;

Step 5, centrifugal by magnetic particle-leucocyte mixture and other cell separation, obtain containing CTC or other rare cells and a small amount of leukocytic mixed cellularity group;

Step 6, uses Immunofluorescence and the method combined of fluorescence in situ hybridization, measures the state of ERCC1/CEP19, carry out the discriminating of CTC or other rare cells simultaneously.

Method of the present invention, wherein, damping fluid described in step 2 is a kind of damping fluid close with density of blood, containing materials such as BSA, PBS, between pH7-8, while can ensureing to remove blood plasma, protects various karyocyte.

Method of the present invention, wherein, erythrocyte cracked liquid described in step 3 is a kind of erythrocyte cracked liquid, utilizes isotonic anisotonic principle, while splitting erythrocyte, can not damage other karyocytes.

Lysate as following formula:

NH4Cl82.9g

KHCO310g

EDTA0.37g

Add H2O to 1000ml (autoclaving, 4 DEG C of preservations)

Or

Erythrocyte cracked liquid (Tris-NH4Cl): take 3.735g ammonium chloride, trishydroxymethylaminomethane (Tris) 1.3g is dissolved in water and is diluted to 500ml.0.22 μm of membrane filtration is degerming, 4 DEG C of preservations.

Method of the present invention, wherein, the magnetic particle being coated with anti-human leucocyte associated antigen described in step 4 is that a kind of bag is by the streptavidin magnesphere of anti-leukocyte common antigen (LCA) antibody.Can maximum ground, securely in conjunction with leucocyte, be beneficial to follow-up sorting process.

Method of the present invention, wherein centrifugation medium described in step 5 is the density gradient centrifugation liquid of a kind of density between 1.070-1.080, wherein optimum with 1.072, removing in conjunction with magnetic bead leukocytic while, other single karyocytes can be preserved and do not lose.

Method of the present invention, wherein, uses the method for Immunofluorescence and fluorescence in situ hybridization described in step 6, carry out CTC discriminating to CTC or other rare cells, Simultaneously test ERCC1/CEP19, method is as follows:

(1) ERCC1 amplification type CTC: observe under sample being placed in fluorescent microscope respective channel, if find multiple ERCC1 signaling point distribution (>=3), and the signal that number is greater than CEP19 is counted, and without CD45 antigen presentation, then count a CTC positive cell, and be directly ERCC1 positive cell depending on this cell;

(2) chromosome amplification type CTC: count single karyocyte CEP19 signal number, if be more than or equal to 3 signaling points and without CD45 antigen presentation, then count a CTC positive cell;

(3) ERCC1/CEP19-CTC total number: record all ERCC1 amplification types and chromosome amplification type CTC number, summation is considered as ERCC1/CEP19-CTC total number;

(4) ERCC1 gene magnification state recording: if there is obvious and typical ERCC1 to increase in all specimen area, be then designated as ERCC1 amplification; If nothing, then by the result of ERCC1 and CEP19 signal ratio in CEP19 number of signals, average each nucleus in ERCC1 number of signals, average each nucleus in each nucleus average in all CTC cells.

A kind of kit one for said method, comprises following composition:

Wherein, 10 ×, 20 × represent concentration, namely this solution is the concentration of 10 times/20 times.

Kit preparation method of the present invention is as follows:

Kit one comprises following enrichment and differentiates two-part reagent.

Enriching section:

CS1 concentrates damping fluid (10 ×):

In every 1000mL water, containing 60gBSA, 5 bags PBS powder (2L/ bag), the EDTA of 100mL0.5M, 0.8mLProclin300.

CS2 concentrates storage liquid (10 ×):

In every 1000mL water, take 82.9gNH ₄cl, 10gKHCO ₃, 0.37gEDTA, water and 0.8mLProclin300, carry out sufficient stirring and dissolving, constant volume, is formulated as 10X concentrate.

CS3 separating medium:

Be the gradient centrifugation liquid dilution of 1.077 by density, test density in dilution, makes its density between 1.070-1.075.

Magnetic particle suspension:

CD45 antibody concentration is adjusted to 1mg/mL, carries out hatching 1h according to the ratio of 100uL:1mL with streptavidin immunomagnetic beads, be namely formulated as magnetic particle suspension.

Differentiate part:

CF1 immobile liquid:

Mixing PEG and absolute ethyl alcohol, make PEG final concentration be 1%, absolute ethyl alcohol final concentration is 50%.

10 × CF2 immobile liquid:

Take PBS as solvent, dissolve PFA powder, be formulated as the PFA concentrate of 5%.

Formamide working fluid:

By the working fluid that the dilution of formamide stoste is 50%.

20XSSC concentrates damping fluid:

In 1000mL water, add sodium chloride 175.3g, ammonium citrate 88.2g.

ERCC1/CEP19 probe:

Use formamide, dextran sulfate sodium salt by ERCC1 and CEP19, be formulated as probe face liquid.

BSA powder:

Outsourcing packing.

CD45-AF594 fluorescence antibody:

CD45 antibody and AlexaFlour594 fluorescein lucifuge are hatched 1h, and fluorescein can be connected with CD45 antibody.

DAPI dyeing liquor:

Use anti-quencher Mountingmedium the DAPI stoste of 1mg/mL to be diluted according to 1:1000, be formulated as DAPI dyeing working fluid.

The using method of kit one of the present invention, step is as follows:

(1) 0.1-5mL blood preparation is added in 50mL centrifuge tube, adds the CS1 working fluid that diluted to 45mL, centrifugal 5 minutes of 650 × g, inhale and abandon supernatant and remain about 12mL liquid;

(2) jog mixing, adds the CS2 cracking working fluid that dilute to 45mL, mixes centrifugal 5 minutes of 8-10 minute, 650 × g, and supernatant fluid is abandoned in suction;

(3) add the mixing of CS1 working fluid appropriate also jog, again add a certain amount of CS1 working fluid, add cleaned magnetic particle suspension 200uL, level shakes up (120rpm) 20 minutes;

(4) draw the rear liquid of all mixings, be superimposed on CS3 separating medium, centrifugal 5 minutes of 300 × g;

(5) the upper two-layer liquid of absorption except magnetic particle precipitation is in 15mL centrifuge tube, adds CS1 working fluid to 15mL, centrifugal 5 minutes of 950 × g, inhales and abandon supernatant;

(6) add 1mLCS1 working fluid, piping and druming mixes and is added in new 2mL centrifuge tube, magnetic separating 2 minutes.Transfer supernatant, in 1.5mL centrifuge tube, is placed on 15mL centrifuge tube, centrifugal 3 minutes of 3400rpm.

(7) supernatant is abandoned in suction, adds CF1 immobile liquid, and piping and druming mixing also smear, dries naturally;

(8) CF2 steady job liquid is added, timing 8-10 minute;

(9) inhale and abandon liquid, put into 2 × SSC dye vat 10 minutes of preheating;

(10) put into 75% successively, 85%, absolute ethyl alcohol 2-5 minute;

(11) add 10uLERCC1/CEP19 probe, covered, mounting also puts into hybridization instrument or other temperature regulating devices, 76 DEG C 5 minutes, 37 DEG C of 4-20 hour;

(12) take out sample, mounting material of tearing, puts into the formamide working fluid of preheating, timing 15 minutes;

(13) 2 × SSC 5-10 minute is placed in;

(14) take out, add the CD45-AF594 fluorescence antibody (20uL antibody+180uL2%BSA) prepared, every slide 200uL, lucifuge reaction 1-5 hour;

(15) surplus liquid is abandoned in suction, and 0.2%BSA cleaning 1-3 time, adds DAPI counterstain 10uL, mounting.The present invention also provides another for the kit two of the inventive method, comprises following composition:

Wherein, 10 ×, 20 × represent concentration, namely this solution is the concentration of 10 times/20 times.

Kit two comprises the reagent of following discriminating part.

Differentiate part:

CF1 immobile liquid:

Mixing PEG and absolute ethyl alcohol, make PEG final concentration be 1%, absolute ethyl alcohol final concentration is 50%.

10 × CF2 immobile liquid:

Take PBS as solvent, dissolve PFA powder, be formulated as the PFA concentrate of 5%.

Formamide working fluid:

By the working fluid that the dilution of formamide stoste is 50%.

20XSSC concentrates damping fluid:

In 1000mL water, add sodium chloride 175.3g, ammonium citrate 88.2g.

ERCC1/CEP19 probe:

Use formamide, dextran sulfate sodium salt by ERCC1 and CEP19, be formulated as probe face liquid.

BSA powder:

Outsourcing packing.

CD45-AF594 fluorescence antibody:

CD45 antibody and AlexaFlour594 fluorescein lucifuge are hatched 1h, and fluorescein can be connected with CD45 antibody.

DAPI dyeing liquor:

Use anti-quencher Mountingmedium the DAPI stoste of 1mg/mL to be diluted according to 1:1000, be formulated as DAPI dyeing working fluid.

The using method of described kit two, step is as follows:

(1) by the cell suspension that this method step (7) or additive method obtain, be applied on microslide or diaphragm, and naturally dry.Add CF2 steady job liquid, timing 8-10 minute;

(2) inhale and abandon liquid, put into 2 × SSC dye vat 10 minutes of preheating;

(3) put into 75% successively, 85%, absolute ethyl alcohol 2-5 minute;

(4) add 10uLERCC1/CEP19 probe, covered, mounting also puts into hybridization instrument or other temperature regulating devices, 76 DEG C 5 minutes, 37 DEG C of 4-20 hour;

(5) take out sample, mounting material of tearing, puts into the formamide working fluid of preheating, timing 15 minutes;

(6) 2 × SSC 5-10 minute is placed in;

(7) take out, add the CD45-AF594 fluorescence antibody (20uL antibody+180uL2%BSA) prepared, every slide 200uL, lucifuge reaction 1-5 hour;

(8) surplus liquid is abandoned in suction, and 0.2%BSA cleaning 1-3 time, adds DAPI counterstain 10uL, mounting.

Microscope can be utilized after mounting to carry out the differentiation of result, can differentiate CTC or other rare cells, obtain number, the number of chromosome amplification type CTC, the total number of ERCC1/CEP19-CTC, the ERCC1 gene magnification state of ERCC1 amplification type CTC simultaneously.

Note: in processing procedure, visual actual conditions, use the punching agent such as TritonX-100, Saponin (but being not limited to these two kinds punching agent) to carry out punching process, to reduce the resistance that probe enters cell to cell.

The present invention further provides the purposes of kit of the present invention, namely at discriminating CTC simultaneously, this kit can also measure ERCC1/CEP19 result, for this reason, the invention reside in and provide kit of the present invention at discriminating CTC simultaneously, ERCC1/CEP19 result can also be measured to judge in the gene appearance that tumor patient is real-time

Application.

Explanation of nouns:

Rare cell: the ratio of occupying in its all karyocytes in body fluid sample is less than 0.1%.Comprise CTC, circulating endothelial cells, fetal cell, tumor stem cell, stem cell, and some immunocyte etc.

Circulating tumor cell (CirculatingTumorCell, CTC): refer to the tumour cell entering into blood circulation.

Noun in form:

Embodiment

Further illustrate the present invention by the following examples, but not as limitation of the present invention.

Embodiment 1

Kit a pair blood sample is used to detect

As shown in above-mentioned kit using method 1-6 step, test 40 routine normal persons, 40 routine lung benign diseases, 20 routine blood of patients with lung cancer samples, method, for be added in 50mL centrifuge tube by 3.2mL blood preparation, adds CS1 working fluid, centrifugal 5 minutes of 650 × g, inhales and abandons supernatant; Add CS2 working fluid cracking 8 minutes, centrifugal 5 minutes of 650 × g, inhale and abandon supernatant fluid; Again add a certain amount of CS1 working fluid, add magnetic particle suspension 200uL, shake up 20 minutes; Draw the rear liquid of all mixings, be superimposed on CS3 separating medium, centrifugal 5 minutes of 300 × g; The liquid of absorption except magnetic particle precipitation, in 15mL centrifuge tube, adds CS1 working fluid to 15mL, centrifugal 5 minutes of 950 × g, inhales and abandon supernatant; Add 1mLCS1 working fluid, piping and druming mixes and is added in new 2mL centrifuge tube, magnetic separating 2 minutes.Transfer supernatant, in 1.5mL centrifuge tube, is placed on 15mL centrifuge tube, centrifugal 3 minutes of 3400rpm.Supernatant is abandoned in suction, adds CF1 immobile liquid, and piping and druming mixing also smear, dries naturally; Add CF2 steady job liquid 8 minutes; Liquid is abandoned in suction, puts into 2 × SSC dye vat 10 minutes of preheating; Put into 75% successively, 85%, absolute ethyl alcohol dehydration 2 minutes; Add 10uLERCC1/CEP19 probe, covered, mounting also puts into hybridization instrument or other temperature regulating devices, 76 DEG C 5 minutes, 37 DEG C 4 hours; Take out sample, throw off cover glass, put into the formamide working fluid 15 minutes of preheating; Be placed in 2 × SSC washing 5 minutes; Add the CD45-AF594 fluorescence antibody (20uL antibody+180uL2%BSA) prepared, every slide 200uL, lucifuge reacts 1 hour; Surplus liquid is abandoned in suction, and 0.2%BSA cleaning 1-3 time, adds DAPI counterstain 10uL, mounting.

Result shows, 18 routine ERCC1 amplification type CTC in pernicious patient, median 4.5/3.2mL (scope 2-29), CEP19 amplification type CTC all detect in 20 routine pernicious patients, median 7 (scope 3-60), and all without detecting in normal person and optimum patient.

Embodiment 2

The preparation of kit of the present invention

Kit one:

CS1 concentrates damping fluid (10 ×):

In every 1000mL water, containing 60gBSA, 5 bags PBS powder (2L/ bag), the EDTA of 100mL0.5M, 0.8mLProclin300.

CS2 concentrates storage liquid (10 ×):

In every 1000mL water, take 82.9gNH ₄cl, 10gKHCO ₃, 0.37gEDTA, water and 0.8mLProclin300, carry out sufficient stirring and dissolving, constant volume, is formulated as 10X concentrate.

CS3 separating medium:

Be the gradient centrifugation liquid dilution of 1.077 by density, test density in dilution, makes its density between 1.070-1.075.

Magnetic particle suspension:

CD45 antibody concentration is adjusted to 1mg/mL, carries out hatching 1h according to the ratio of 100uL:1mL with streptavidin immunomagnetic beads, be namely formulated as magnetic particle suspension.

CF1 immobile liquid:

Mixing PEG and absolute ethyl alcohol, make PEG final concentration be 1%, absolute ethyl alcohol final concentration is 50%.

10 × CF2 immobile liquid:

Take PBS as solvent, dissolve PFA powder, be formulated as the PFA concentrate of 5%.

Formamide working fluid:

By the working fluid that the dilution of formamide stoste is 50%.

20XSSC concentrates damping fluid:

In 1000mL water, add sodium chloride 175.3g, ammonium citrate 88.2g.

ERCC1/CEP19 probe:

Use formamide, dextran sulfate sodium salt by ERCC1 and CEP19, be formulated as probe face liquid.

BSA powder:

Outsourcing packing.

CD45-AF594 fluorescence antibody:

CD45 antibody and AlexaFlour594 fluorescein lucifuge are hatched 1h, and fluorescein can be connected with CD45 antibody.

DAPI dyeing liquor:

Use anti-quencher Mountingmedium the DAPI stoste of 1mg/mL to be diluted according to 1:1000, be formulated as DAPI dyeing working fluid.

Kit two only comprises 5)-12) part, preparation method is identical.

Embodiment 3

Detect with kit of the present invention a pair other body fluid sample

Illustrate: this kit is not only applicable to blood, be also applicable to the detection of rare cell in other body fluid, such as hydrothorax, ascites, washing liquid, amniotic fluid etc., but be not limited to this several body fluid.

Use this kit to detect 13 routine cells in pleural fluids from lung cancer cases, all find CEP19 amplification type positive cell, positive rate 100%, 12 examples find ERCC1 amplification type positive cell, median 16 (scope 11-90).Embodiment 4

The CTC using kit two pairs of additive methods to get detects

Illustrate: the component in kit two, namely ERCC1/CEP19 probe, CD45-AF594 fluorescence antibody, DAPI dyeing liquor etc., be also applicable to the CTC that additive method gets, such as filtration method, ChIP method etc., but be not limited to this two kinds of methods.

Using membrane filter method to process 26 routine peripheral blood of lung cancer patients samples, is the Ispore of 8um by diameter ^tMmembraneFilters coordinate SWINNEX filter with the use of.Concrete grammar is, first 5mL blood preparation and 10mLPBS is mixed, is added in filtrator, and by Action of Gravity Field natural subsidence, CTC is comparatively large because of volume, stays film surface, is transferred on standard glass slide by filter membrane.After drying, carry out dyeing process according to the method for operating of kit two to CTC, method is as follows: by dried sample through CF2 steady job liquid 8 minutes; Liquid is abandoned in suction, puts into 2 × SSC dye vat 10 minutes of preheating; Put into 75% successively, 85%, absolute ethyl alcohol dehydration 2 minutes; Add 10uLERCC1/CEP19 probe, covered, mounting also puts into hybridization instrument or other temperature regulating devices, 76 DEG C 5 minutes, 37 DEG C 4 hours; Take out sample, throw off cover glass, put into the formamide working fluid 15 minutes of preheating; Be placed in 2 × SSC washing 5 minutes; Add the CD45-AF594 fluorescence antibody (20uL antibody+180uL2%BSA) prepared, every slide 200uL, lucifuge reacts 1 hour; Surplus liquid is abandoned in suction, and 0.2%BSA cleaning 1-3 time, adds DAPI counterstain 10uL, mounting, and at fluorescence microscopy Microscopic observation.

Result is added up, and it is positive that 25 examples show CEP19 amplification type CTC, and 23 routine ERCC1 amplification types are positive.

Claims (10)

1. detect a method for ERCC1/CEP19 gene appearance based on rare cell, it is characterized in that, said method comprising the steps of:

Step 1, obtains blood sample from patient or other contain the body fluid sample of rare cell, comprises CTC or other rare cells and leukocytic mixed cellularity group in sample;

Step 2, uses damping fluid diluted sample, centrifugal segregation blood plasma, and reclaims CTC or other rare cells;

Step 3, uses erythrocyte cracked liquid cracking, and centrifugal segregation red blood cell also reclaims CTC or other rare cells;

Step 4, with the recovery cell blending incubation of magnetic particle with step 3 gained being coated with anti-human leucocyte associated antigen, fully to combine with target leucocyte to make magnetic particle and forms magnetic particle-leucocyte mixture;

Step 5, centrifugal by magnetic particle-leucocyte mixture and other cell separation, obtain containing CTC or other rare cells and a small amount of leukocytic mixed cellularity group;

Step 6, uses Immunofluorescence and the method combined of fluorescence in situ hybridization, measures the state of ERCC1/CEP19, carry out the discriminating of CTC or other rare cells simultaneously.

2. method according to claim 1, is characterized in that, damping fluid described in step 2 is damping fluid that is close with density of blood, that comprise BSA and PBS, PH7-8, and wherein, erythrocyte cracked liquid described in step 3 is any one erythrocyte cracked liquid.

3. method according to claim 1, is characterized in that, the magnetic particle being coated with anti-human leucocyte associated antigen described in step 4 be a kind of bag by the streptavidin magnesphere of anti-leukocyte common antigen (LCA) antibody, can securely in conjunction with leucocyte.

4. method according to claim 1, is characterized in that, centrifugation medium described in step 5 is the density gradient centrifugation liquid of a kind of density between 1.070-1.080.

5. method according to claim 1, is characterized in that, uses the method for Immunofluorescence and fluorescence in situ hybridization described in step 6, and measure ERCC1/CEP19, differentiate CTC or other rare cells, method is as follows:

(1) ERCC1 amplification type CTC: observe under sample being placed in fluorescent microscope respective channel, if find multiple ERCC1 signaling point distribution (>=3), and the signal that number is greater than CEP19 is counted, and without CD45 antigen presentation, then count a CTC positive cell, and be directly ERCC1 positive cell depending on this cell;

(2) chromosome amplification type CTC: count single karyocyte CEP19 signal number, if be more than or equal to 3 signaling points and without CD45 antigen presentation, then count a CTC positive cell;

(3) ERCC1/CEP19-CTC total number: record all ERCC1 amplification types and chromosome amplification type CTC number, summation is considered as ERCC1/CEP19-CTC total number;

(4) ERCC1 gene magnification state recording: if there is obvious and typical ERCC1 to increase in all specimen area, be then designated as ERCC1 amplification; If nothing, then by the result of ERCC1 and CEP19 number of signals ratio in CEP19 number of signals, average each nucleus in ERCC1 number of signals, average each nucleus in each nucleus average in all CTC cells.

6. for a kit for claim 1 method, it is characterized in that, comprise following composition:

CS1 concentrates damping fluid (10 ×)

CS2 concentrates storage liquid (10 ×)

CS3 separating medium

Magnetic particle suspension

CF1 immobile liquid

10 × CF2 immobile liquid

DAPI dyeing liquor

ERCC1/CEP19 probe

CD45-AF594 fluorescence antibody

Formamide working fluid

20 × SSC concentrates damping fluid

BSA。

7. the using method of kit described in claim 6, is characterized in that, step is as follows:

(1) 0.1-5mL blood preparation is added in 50mL centrifuge tube, adds the CS1 working fluid that diluted to 45mL, centrifugal 5 minutes of 650 × g, inhale and abandon supernatant and remain about 12mL liquid;

(2) jog mixing, adds the CS2 cracking working fluid that dilute to 45mL, mixes centrifugal 5 minutes of 8-10 minute, 650 × g, and supernatant fluid is abandoned in suction;

(3) add the mixing of CS1 working fluid appropriate also jog, again add a certain amount of CS1 working fluid, add cleaned magnetic particle suspension 200uL, level shakes up (120rpm) 20 minutes;

(4) draw the rear liquid of all mixings, be superimposed on CS3 separating medium, centrifugal 5 minutes of 300 × g;

(5) the upper two-layer liquid of absorption except magnetic particle precipitation is in 15mL centrifuge tube, adds CS1 working fluid to 15mL, centrifugal 5 minutes of 950 × g, inhales and abandon supernatant;

(6) add 1mLCS1 working fluid, piping and druming mixes and is added in new 2mL centrifuge tube, magnetic separating 2 minutes.Transfer supernatant, in 1.5mL centrifuge tube, is placed on 15mL centrifuge tube, centrifugal 3 minutes of 3400rpm;

(7) supernatant is abandoned in suction, adds CF1 immobile liquid, and piping and druming mixing also smear, dries naturally;

(8) CF2 steady job liquid is added, timing 8-10 minute;

(9) inhale and abandon liquid, put into 2 × SSC dye vat 10 minutes of preheating;

(10) put into 75% successively, 85%, absolute ethyl alcohol 2-5 minute;

(11) add 10uLERCC1/CEP19 probe, covered, mounting also puts into hybridization instrument or other temperature regulating devices, 76 DEG C 5 minutes, 37 DEG C of 4-20 hour;

(12) take out sample, mounting material of tearing, puts into the formamide working fluid of preheating, timing 15 minutes;

(13) 2 × SSC 5-10 minute is placed in;

(14) take out, add the CD45-AF594 fluorescence antibody (20uL antibody+180uL2%BSA) prepared, every slide 200uL, lucifuge reaction 1-5 hour;

(15) surplus liquid is abandoned in suction, and 0.2%BSA cleaning 1-3 time, adds DAPI counterstain 10uL, mounting.

8. for a kit for claim 1 method, it is characterized in that, comprise following composition:

CF1 immobile liquid

10 × CF2 immobile liquid

DAPI dyeing liquor

ERCC1/CEP19 probe

CD45-AF594 fluorescence antibody

Formamide working fluid

20 × SSC concentrates damping fluid

BSA。

9. the using method of kit described in claim 8, is characterized in that step is as follows:

(1) by the cell suspension that this method step (7) or additive method obtain, be applied on microslide or diaphragm, and naturally dry, add CF2 steady job liquid, timing 8-10 minute;

(2) inhale and abandon liquid, put into 2 × SSC dye vat 10 minutes of preheating;

(3) put into 75% successively, 85%, absolute ethyl alcohol 2-5 minute;

(4) add 10uLERCC1/CEP19 probe, covered, mounting also puts into hybridization instrument or other temperature regulating devices, 76 DEG C 5 minutes, 37 DEG C of 4-20 hour;

(5) take out sample, mounting material of tearing, puts into the formamide working fluid of preheating, timing 15 minutes;

(6) 2 × SSC 5-10 minute is placed in;

(7) take out, add the CD45-AF594 fluorescence antibody (20uL antibody+180uL2%BSA) prepared, every slide 200uL, lucifuge reaction 1-5 hour;

(8) surplus liquid is abandoned in suction, and 0.2%BSA cleaning 1-3 time, adds DAPI counterstain 10uL, mounting.

10. claim 6 or 8 any one kit is while mensuration rare cell, detects the application of ERCC1/CEP19 gene appearance.